IP Library › Granted Patent US 7,553,496
Granted Patent B2
US 7,553,496 · App. 11/017,201 · Granted Jun 30, 2009

VEGF-A as an inhibitor of angiogenesis and methods of using same

Assignee: University of Kentucky Research Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,553,496
App. No.
11/017,201
Granted
Jun 30, 2009
Kind
B2
Abstract

The invention relates to methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization associated with neovascular disease. Administration of vascular endothelial growth factor (VEGF)-A into the eye when macrophage infiltration is reduced inhibits ocular angiogenesis.

Claims (4)

1. An ophthalmic composition for treatment of ocular neovascularization comprising an effective amount of a SPARC antagonist, a compound selected from VEGF-A, PLGF-1 and PLGF-2, and a pharmaceutically acceptable carrier suitable for injection into the eye or topical application to the eye, wherein said composition inhibits ocular neovascularization.

2. The composition of claim 1 wherein the SPARC antagonist is an antibody to SPARC or antibody fragment that binds to SPARC.

3. The composition of claim 1 wherein the SPARC antagonist is siRNA that binds to and inhibits expression of the SPARC gene.

4. The composition of claim 1 wherein the SPARC antagonist is a peptide that binds to and inhibits the active site of SPARC.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2005
From: AMBATI, JAYAKRISHNA
To: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
Reel/Frame 016659/0046 →
Continuity (1)
Related Publication 20060135423A1 · Jun 22, 2006